In 2025, everyone enrolled in Part D will have their annual out-of-pocket drug costs capped at $2,000. In future years, that cap will rise in step with the rate of change in Part D costs.

A constitutional challenge to the Biden administration program enabling Medicare to negotiate lower prices for prescription ...

A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...

A U.S. appeals court revived a lawsuit on Friday by healthcare and drug industry groups challenging the first-ever U.S. law ...

The US Food and Drug Administration (FDA) has declined to approve the new drug application (NDA) submitted by Vanda ...

Explore the top 7 quantum computing applications that are driving new technological advancements. Can quantum computing become a game-changer?

That’s according to police, who allege the $20,000 deal was one of several done between February and May by members of an ...

Channel 13's Abel Garcia met with a local and a doctor to get your questions and concerns answered over new weight loss drugs LAS VEGAS (KTNV) — Chances are you or someone you know is taking one ...

The application is supported by data from the randomized, double-blind, placebo-controlled, phase 3 CheckMate -77T trial (ClinicalTrials.gov Identifier: NCT04025879). Study participants were ...

Shilpa Medicare (SML) climbed 6.12% to Rs 811.25 after the company announced that it has submitted new drug application (NDA) to U.S. Food and Drug Administration (USFDA) for Oxylanthanum Carbonate.

PBRERs will be received, processed, and tracked, using a single window approach using the Drug Submission Tracking System (DSTS) through the Office of Submissions and Intellectual Property (OSIP).

Currently, Granules has 16 ANDAs (abbreviated new drug applications) pending for approval from the FDA, and 11 are from the Gagilapur facility. The regulatory body has so far approved 36 ANDAs ...